Cardiome Pharma (CRME) Misses Q3 EPS by 2c

Cardiome Pharma (NASDAQ: CRME) reported Q3 EPS of ($0.20), $0.02 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $6 million versus the consensus estimate of $7.42 million.

GUIDANCE:

Cardiome Pharma sees FY2017 revenue of $24-26 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M